Skip to main content

CORRECTION article

Front. Immunol., 16 August 2023
Sec. Cancer Immunity and Immunotherapy
This article is part of the Research Topic Liquid Biopsies in Hematological Malignancies View all 8 articles

Corrigendum: Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients

Ana Jimnez-Ubieto*&#x;Ana Jiménez-Ubieto1*†Alejandro Martín-Muoz,&#x;Alejandro Martín-Muñoz1,2†María PozaMaría Poza1Sara Dorado,Sara Dorado2,3Almudena García-OrtizAlmudena García-Ortiz1Enrique RevillaEnrique Revilla4Pilar SarandesesPilar Sarandeses5Yanira Ruiz-Heredia,Yanira Ruiz-Heredia1,2Tycho BaumannTycho Baumann1Antonia RodríguezAntonia Rodríguez1María CalbachoMaría Calbacho1Pilar Martínez SnchezPilar Martínez Sánchez1Jos María Snchez PinaJosé María Sánchez Pina1Alejandro Martín García-SanchoAlejandro Martín García-Sancho6Gloria FigaredoGloria Figaredo1Laura Rufin,Laura Rufián1,2Margarita Rodríguez,Margarita Rodríguez1,2Laura CarnerosLaura Carneros1Carolina Martínez-LapercheCarolina Martínez-Laperche7Mariana Bastos-OreiroMariana Bastos-Oreiro7Chongwu WangChongwu Wang8María-Teresa CedenaMaría-Teresa Cedena1Inmaculada RapadoInmaculada Rapado1Paula de ToledoPaula de Toledo3Miguel GallardoMiguel Gallardo1Antonio ValeriAntonio Valeri1Rosa AyalaRosa Ayala1Joaquín Martínez-LpezJoaquín Martínez-López1Santiago Barrio,*Santiago Barrio1,2*
  • 1Department of Hematology, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), CNIO, CIBERONC, Madrid, Spain
  • 2Altum sequencing Co., Madrid, Spain
  • 3Computational Science Department, Carlos III University, Madrid, Spain
  • 4Departamento de Anatomía Patológica, Hospital Universitario 12 de Octubre, Madrid, Spain
  • 5Departamento de Medicina Nuclear, Hospital Universitario 12 de Octubre, Madrid, Spain
  • 6Department of Hematology, Hospital Universitario de Salamanca, IBSAL, CIBERONC, Salamanca, Spain
  • 7Hospital General Universitario Gregorio Marañón, Madrid, Spain
  • 8Hosea Precision Medical Technology Co., Ltd., Weihai, Shangdong, China

A Corrigendum on
Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients.

By Jiménez-Ubieto A, Martín-Muñoz A, Poza M, Dorado S, García-Ortiz A, Revilla E, Sarandeses P, Ruiz-Heredia Y, Baumann T, Rodríguez A, Calbacho M, Sánchez PM, Pina JMS, García-Sancho AM, Figaredo G, Rufián L, Rodríguez M, Carneros L, Martínez-Laperche C, Bastos-Oreiro M, Wang C, Cedena M-T, Rapado I, de Toledo P, Gallardo M, Valeri A, Ayala R, Martínez-López J and Barrio S (2023). Front. Immunol. 14:1188818. doi: 10.3389/fimmu.2023.1188818

In the published article, there was an error in the author list, and author Miguel Gallardo was erroneously excluded. The corrected author list appears below:

Ana Jiménez-Ubieto1*†, Alejandro Martı´n-Muñoz1,2†,María Poza1, Sara Dorado2,3, Almudena García-Ortiz1, Enrique Revilla4, Pilar Sarandeses5, Yanira Ruiz-Heredia1,2, Tycho Baumann1, Antonia Rodríguez1, María Calbacho1, Pilar Martínez Sánchez1, José María Sánchez Pina1, Alejandro Martín García-Sancho6, Gloria Figaredo1, Laura Rufián1,2, Margarita Rodríguez1,2, Laura Carneros1, Carolina Martínez-Laperche7, Mariana Bastos-Oreiro7, Chongwu Wang8, María-Teresa Cedena1, Inmaculada Rapado1, Paula de Toledo3, Miguel Gallardo1, Antonio Valeri1, Rosa Ayala1, Joaquín Martínez-López1 and Santiago Barrio1,2.

The updated author contribution section appears below:

AJ-U, AM-M, MP, and SB designed the research. LR, AG-O, ER, PS and MR performed the experiments. AM-M, YR-H, SD, CW, and SB defined the bioinformatic pipeline and performed sequencing data analysis. AJ-U, MP, ER, TB, AR, MC, GF, M-TC, RA and JM-L provided patient samples and clinical data. Author MG contributed to the conception, design and manuscript revisions. All authors analyzed and interpreted the data. AJ-U, AM-M, MP, and SB wrote the manuscript which was approved by all authors.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: follicular lymphoma, ctDNA (circulating tumor DNA), NGS (Next-Generation Sequencing), minimal residual disease, monitoring, PET/CT 18F-FDG, CAR T-cell therapy

Citation: Jiménez-Ubieto A, Martín-Muñoz A, Poza M, Dorado S, García-Ortiz A, Revilla E, Sarandeses P, Ruiz-Heredia Y, Baumann T, Rodríguez A, Calbacho M, Sánchez PM, Pina JMS, García-Sancho AM, Figaredo G, Rufián L, Rodríguez M, Carneros L, Martínez-Laperche C, Bastos-Oreiro M, Wang C, Cedena M-T, Rapado I, de Toledo P, Gallardo M, Valeri A, Ayala R, Martínez-López J and Barrio S (2023) Corrigendum: Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients. Front. Immunol. 14:1243241. doi: 10.3389/fimmu.2023.1243241

Received: 20 June 2023; Accepted: 08 August 2023;
Published: 16 August 2023.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2023 Jiménez-Ubieto, Martín-Muñoz, Poza, Dorado, García-Ortiz, Revilla, Sarandeses, Ruiz-Heredia, Baumann, Rodríguez, Calbacho, Sánchez, Pina, García-Sancho, Figaredo, Rufián, Rodríguez, Carneros, Martínez-Laperche, Bastos-Oreiro, Wang, Cedena, Rapado, de Toledo, Gallardo, Valeri, Ayala, Martínez-López and Barrio. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Ana Jiménez-Ubieto, anitiju@hotmail.com; Santiago Barrio, santiago_barrio@altumsequencing.com

These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.